Curated News
By: NewsRamp Editorial Staff
April 01, 2025
LisenID and Mayo Clinic Collaborate on Innovative Cancer Diagnostics
TLDR
- LisenID partners with Mayo Clinic to develop advanced early cancer diagnostics, providing a competitive edge in accurate and timely detection.
- LisenID's QCIGISH technology detects cancer through epigenetic imprinting biomarker abnormalities, enhancing early diagnosis accuracy and enabling precise treatments.
- The collaboration between LisenID and Mayo Clinic aims to improve patient outcomes by advancing early cancer detection methods, ultimately enhancing global healthcare.
- LisenID's innovative QCIGISH technology revolutionizes early cancer diagnosis, offering a promising solution for detecting various cancers at the earliest stages.
Impact - Why it Matters
This news matters as it highlights a groundbreaking collaboration between LisenID and Mayo Clinic to enhance early cancer diagnosis. The partnership signifies a significant step towards improving patient outcomes and reducing unnecessary treatments by introducing innovative technology for detecting cancer at its inception.
Summary
Lisen Imprinting Diagnostic, Inc. (LisenID) has partnered with Mayo Clinic to develop advanced early cancer diagnostic solutions, combining LisenID's epigenetic imprinting technology with Mayo Clinic's clinical expertise. The collaboration aims to improve early cancer detection through innovative Quantitative Chromogenic Imprinted Gene In-Situ Hybridization (QCIGISH) technology.
The focus of the collaboration is to create a laboratory-developed test (LDT) for early lung cancer detection using TBNA samples. This test, based on QCIGISH, promises more accurate and clinically actionable results for diagnosing malignancies in peripheral pulmonary lesions (PPLs), which are currently challenging to detect.
Source Statement
This curated news summary relied on this press release disributed by Reportable. Read the source press release here, LisenID and Mayo Clinic Collaborate on Innovative Cancer Diagnostics
